Inventiva (IVA) Net Income towards Common Stockholders (2019 - 2025)

Inventiva's (IVA) quarterly Net Income towards Common Stockholders came in at $880664.6 in Q2 2025, up 1268.27% year-on-year from $64363.5 in Q2 2024, and up 1277.33% quarter-over-quarter from -$74801.7 in Q4 2024.

Inventiva (IVA) Net Income towards Common Stockholders (2019 - 2025) Analysis & Trends

Inventiva's Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at $880664.6 for Q2 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 1268.27% year-over-year to $880664.6 in Q2 2025; TTM through Dec 2025 was $730480.8, a 284.7% increase from a year earlier, with the FY2025 full-year figure at -$411.9 million, down 55275.39% from the prior year.
  • Net Income towards Common Stockholders grew to $880664.6 in Q2 2025 per IVA's latest filing, from -$74801.7 in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $880664.6 in Q2 2025 and bottomed at -$11.9 million in Q2 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$178852.7 (2022), against an average of -$2.1 million.
  • Across the five-year window, Net Income towards Common Stockholders dropped 23.09% in 2021 and jumped 1268.27% in 2025, its largest moves.
  • Year by year, Net Income towards Common Stockholders stood at -$11.9 million in 2021, then jumped by 98.03% to -$234656.9 in 2022, then decreased by 4.54% to -$245314.3 in 2023, then surged by 69.51% to -$74801.7 in 2024, then soared by 1277.33% to $880664.6 in 2025.
  • Per Business Quant, the three latest IVA Net Income towards Common Stockholders figures stand at $880664.6 (Q2 2025), -$74801.7 (Q4 2024), and -$75382.1 (Q2 2024).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -625.73
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 62.72 Bn 62.72 Bn - -0.68
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 472.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - -453.82 Mn
10 Inventiva 854.62 Mn 854.62 Mn - -

Historic Data

Download Data
DateValue
Jun 30, 2025 880,664.64
Dec 31, 2024 -74,801.68
Jun 30, 2024 -75,382.13
Dec 31, 2023 -245,314.30
Jun 30, 2023 -123,048.46
Dec 31, 2022 -234,656.89
Jun 30, 2021 -11.94 Mn
Mar 31, 2021 -5.24 Mn
Dec 31, 2020 -35.43 Mn
Jun 30, 2020 -9.70 Mn
Mar 31, 2020 -7.48 Mn
Dec 31, 2019 -33.34 Mn